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ABSTRACT 
 
Due to the high prevalence of viral infections having no specific treatment and the constant appearance of 
resistant viral strains, the development of novel antiviral agents is essential. The aim of this study was to 
evaluate the antiviral activity of aqueous and ethanolic extracts of Aeglemarmelos against Influenza A 
(H1N1) pdm09. The extract was subjected to cytotoxicity as well as antiviral activity on MDCK cells. The 
concentration range from 10 to 100μg/ml in MDCK cell line was conducted. It showed that the treated cells 
with drug was nontoxic to the cells at the concentration of 50μg/ml for ethanolic and 60μg /ml for aqueous 
extract at 48 hrs to 72 hrs and was comparable to that of controls.  Hence crude extract of both ethanolic 
and aqueous up to 50-60μg /ml (CC50) could be used to test the antiviral activity without affecting much of 
the cell viability. In simultaneous anti viral assay, 80% viral inhibition was observed at the concentration of 
50μg/ml in aqueous extract whereas 100 % viral inhibition was observed in ethanolic extract at concentra-
tion of 60μg/ml. In the post treatment assay, the aqueous extract did not show viral inhibition, whereas the 
ethanolic extract showed 100% reduction at the concentrations of 60μg/ml. This data suggest that ethanolic 
extract inhibit the Influenza virus infection by blockage of viral attachment by inhibition of viral HA protein, 
this is consistent with previous studies. 
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INTRODUCTION 
Influenza viruses are extremely infective agent to 
cause frequent epidemics and pandemics in humans. 
Yearly about 10% of population were infected and 
the number of deaths occurs (about 250,000) world-
wide. The Influenza virus comes under Orthomyxovir-
idae and further classified into 3 types (Influenza A, B 
and C), Influenza A and B viruses spread all over the 
world and causes epidemics and pandemics through 
antigenic drift and shift. Due to the elevated muta-
genic rate, novel virulent influenza strains can occur 
unpredictably to cause global pandemics with notice-
able increase in morbidity and mortality such as 
avian Influenza virus (H5N1) in 1997 and Influenza A 
(H1N1) pdm09 in 2009. Annual vaccination is the pri-
mary strategy to prevent the influenza virus infec-
tion, but it needs continues surveillance to make vac-
cines based on the circulating virus strains.[1] Antivi-
ral drugs are representing the first line of defense to 
pandemic infection with a novel strain. Currently ex-
isting Influenza drugs are to block the viral replica-
tion and viral spread. Adamantanes referred as first 
generation drugs to Influenza virus and act on the vi-
ral M2 protein by blockers the ion channels.  
Adamantanes side effects associated with the gastro-
intestinal tract, central nervous system and also de-
velop the resistant during treatment and it act on In-
fluenza A viruses only. Neuraminidase inhibitors 
(NAI) are the second generation drugs to Influenza vi-
rus, these are oseltamivir and zanamavir. Zanamavir 
is a sialic acid analogue, and oseltamivir inhibit the si-
alidase activity of the viral neuraminidase by binding 
to active site of NA. Side effects of Neuraminidase in-
hibitors are vomiting, nausea, diarrhea, abdominal 
pain, headache, dizziness and sinusitis,additionally 
Influenza A (H1N1) pdm09 virus was resistant to 
oseltamivir, have been reported worldwide . This 
data suggest that necessity of next generation (third 
generation) drugs to treat the Influenza virus with a 
diverse mode of action. Natural products, especially 
obtained from plant source can be identified as next 
generation antiviral. [2]  
At present, plant resources are relatively unlimited 
for antiviral herbal medicine, but these resources are 
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decreasing quickly due to deforestation and industri-
alization. Although a number of studies have been ex-
ecuted the use of purified plant parts, only a few stud-
ies have answered the antiviral activities of crude 
plant extracts.  
As estimated by WHO, 80% of population in the de-
veloped countries still relies almost on traditional 
medicine for their primary healthcare needs. India is 
one of the largest producer of medicinal herbs and is 
known as the botanical garden of the world. A num-
ber of plants have been shown to possess antiviral ac-
tivities. Aeglemarmelos (L.) whose leaves, flowers, 
fruits and roots are widely used for medicinal value 
compounds against cold, cough, whooping cough, 
chronic bronchitis and asthma as narcotic, expecto-
rant and antispasmodic as conventional medicines. In 
the present study, we have focused on the fruits of Ae-
glemarmelos (L.) crude extract, which were screened 
for antiviral activity against Influenza A (H1N1) 
pdm09. 
Cell lines  
Madin Darby Canine Kidney (MDCK) cell lines were 
obtained from National Centre for Cell Science 
(NCCS) Pune, India and were grown. For all the exper-
iments, controls were included (cell control, virus 
control and positive control). 
Influenza Virus and Titration  
The Influenza A (H1N1) pdm09 strain A/India/Pune 
153793/2015(H1N1) was obtained from National In-
stitute of Virology (NIV) and it was included as a pos-
itive control and Chennai strain A/In-
dia/Che147506/2015(H1N1) confirmed in NIV was 
used for antiviral activity. These strains were grown 
in MDCK cells. After CPE appear, supernatants were 
collected and virus titer (TCID50) was determined 
using with standard protocol. 
Cytotoxicity Assay  
Cytotoxicity assay was performed on MDCK cell lines 
to determine the drug (ethanolic extract and aqueous 
extract) 50% Cytotoxic Concentrations (CC50) using 
with standard protocol. Briefly, after forming a con-
fluent monolayer, the media were removed and by 
the addition of 100 μl of plant extract (dilutions rang-
ing from 10-100μg/ ml) and incubate 37⁰C with 5% 
CO2 for 72 hours. After 72 hours, MTT assay was per-
formed (3- (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide) (MTT, HiMedia, RM1131) and 
optical density (OD) was measured at 620 nm using 
an ELISA micro plate reader (Thermo Multikan EX, 
USA) and calculate the 50% Cytotoxic Concentrations 
(CC50).[3] 
Antiviral assay  
Antiviral activity was carried out by simultaneous 
and post treatment assays. 
Virus binding or Simultaneous Treatment assay  
Simultaneous anti influenza treatment assay was per-
formed to identify, whether extracts block the viral 
adsorption to cells, using a standard protocol. In 
briefly, different concentrations of ethanolic (50, 55 
and 60μg/ml), aqueous extracts (40, 45 and 
50μg/ml) were mixed with virus (1TCID50) and in-
cubated for one hour at 4°C. The mixture was added 
to the MDCK cell line in triplicates along with cell con-
trol, drug control and virus control and wait for one 
hour with irregular shaking4. After one hour, remove 
the solution, add MEM media with 2μg/ml TPCK and 
incubate for 72 hours at 37°C under 5% CO2 and 
every day observed cells under light microscope. Af-
ter 72 hours to estimate the cell viability by perform-
ing the MTT assay.  
To verify the effect of extracts on virus adsorption, 
Haemagglutination inhibition (HAI) test was per-
formed. Before performing the HAI, plant extracts 
were treated with Receptor Destroying Enzyme 
(RDE), the purpose of this treatment was to remove 
the compounds that may having sialic acid like struc-
tures which mimic the receptors of RBC and compete 
for haemagglutinin. 
Penetration or Post Treatment assay 
Post Treatment assay was performed to identify the 
antiinfluenza activity after virus infection, using a 
standard protocol. In briefly, Influenza virus 
(1TCID50) was added to the MDCK cell line and wait 
for one hour with irregular shaking. After one hour, 
the media was removed and substituted with MEM 
media containing different dilutions of drug with 
2μg/ml TPCK were added in triplicates along with 
cell control, drug control and virus control. Incubate 
for 72 hours at 37°C under 5% CO2 and every day ob-
served cells under light microscope. After 72 hours to 
estimate the cell viability by performing the MTT as-
say.[5] 
Statistical analysis  
Statistical Analysis was carried out by using the SPSS 
software version 15.0 (SPSS Inc., Chicago, USA). For 
data analysis, Chi-square test was used, where P< 
0.05 was considered statistically significant. 
Anti viral activity  
Aqueous and ethanolic extracts of Aeglemarmelos 
screened for Influenza A (H1N1) pdm09 (A/In-
dia/Che147506/2015(H1N1) strain) virucidal activ-
ity. These extracts were subjected to cytotoxicity as 
well as antiviral activity on MDCK cells. 
Cytotoxicity studies of plant extracts  
The studies on cytotoxicity of ethanolic and aqueous 
extract of Aeglemarmelos at the concentration range 
from 10 to 100μg/ml in MDCK cell line were con-
ducted. It showed that the treated cells with drug 
were nontoxic to the cells at the concentration of 
50μg/ml for ethanolic and 60μg /ml for aqueous ex-
tract at 48 hrs to 72 hrs and was comparable to that 
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of controls (untreated and DMSO treated cells). How-
ever cells treated with 50μg/ml of the ethanolic ex-
tract and 60μg /ml of aqueous concentration and 
above exhibited toxicity as morphological changes 
observed as loss of monolayer granulation and vacu-
olation in the cytoplasm and cell damage when com-
pared to wells treated with 50μg /ml and less. (Figure 
1, Figure 2, Figure 3) Hence crude extract of both eth-
anolic and aqueous up to 50-60μg /ml (CC50) could 
be used to test the antiviral activity without affecting 
much of the cell viability. 
 
Figure 1: CC50 Concentration of Ethanolic Extract 
 
Figure 2: CC50 Concentration of Aqueous Extract 
 
Figure 3: Cytotoxicity Effect of Aeglemarmelos ex-
tracts on MDCK cell Line 
Measurement of Tissue Culture Influenza Virus 
Infectious Dose (TCID50)  
The Influenza A/India/Che147506/2015(H1N1) 
strain was used to quantify the viral titer by TCID50 
on MDCK cell lines for antiviral activity. CPE was ex-
pressed with a “+”. No CPE was observed at high dilu-
tions in all the wells and CPE was observed at low di-
lutions in all the wells (Table 1). At particular virus 
dilution (10-5 dilution) half of the cell cultures 
showed CPE. This is the end point which was defined 
as the dilution of virus at which 50% of the cell cul-
tures are infected. Estimate the cell viability by per-
forming the MTT assay. This number can be calcu-
lated and expressed as 50% infectious dose (ID50) 
per milliliter. 
RESULTS AND DISCUSSION 
Antiviral activity  
In the present study, both ethanolic and aqueous ex-
tracts were non cytotoxic in the concentration range 
of 10-60μg/ml (Figure 1 and Figure 2). This indicated 
that below the concentration of the extract could be 
used for further antiviral assay. 
Inhibitory activity of Aeglemarmelos on Influenza 
virus binding to cell receptors 
In order to test the ability of the ethanolic and aque-
ous extracts to preventing the attachment of influ-
enza virus to MDCK cells, we used and analysed the 
simultaneous treatment assays. The results showed 
that 80% viral inhibition was observed at a concen-
tration of 60μg/ml in aqueous extract whereas 100% 
viral inhibition was observed in ethanol extract at 
concentration of 50μg/ml as showed in Fig 4. As the 
concentration decreased, the viral inhibition also de-
creased. 
Inhibitory activity of Aeglemarmeloson Influenza 
virus Replication  
Post treatment assay carryout to estimate the anti-in-
fluenza activity after virus infection. In the post treat-
ment assay, the aqueous extract did not show any in-
hibition whereas the ethanol extract showed 100% 
viral inhibition at concentration of 50μg/ml showed 
in Fig 5. As the concentration decreased, the viral in-
hibition also decreased. 
Influenza virus carryon to emerging remerging and 
remains a most important public health concern. As a 
substitute to chemically synthesized antivirals such 
as amantadine or oseltamivir. Many plant extracts 
and purified substance phytochemicals have been 
tested and reported to have selective antiviral activ-
ity inhibiting Influenza viruses.[6] In a similar way 
within the reach for identifying new antiviral sub-
stances of plant origin, the antiviral potential of crude 
extract of Aeglemarmelos was tested against Influ-
enza virus in the present study. The results of the 
phytochemical analysis revealed that alkaloids, phe-
nols, tannins, saponins, anthraquinones, amino acids, 
flavonoids, and reducing sugars are present in the 
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fruits of Aeglemarmelos. In the present study, both 
ethanolic and aqueous extracts were non-cytotoxic in 
the concentration range of 10-50μg/ml his indicated 
that above range of concentration of the extract could 
be used for further antiviral assay.[7] 
The Influenza virus replication cycle can be divided 
into 5 steps: 1. Adsorption 2. Endocytosis and fusion, 
3. Uncoating, 4. Packaging and budding and 5. Re-
lease. In the current study, antiviral activity was car-
ried out by simultaneous and post treatment as-
says.[8] Simultaneous anti-influenza treatment assay 
was performed to identify, whether Aeglemarmelos 
extracts block the viral adsorption to cells.[9] In sim-
ultaneous assay, 80% viral inhibition was observed at 
the concentration of 50μg/ml in aqueous extract 
whereas 100 % viral inhibition was observed in eth-
anolic extract at concentration of 60μg/ml. These 
data suggest that aqueous and ethanolic extracts may 
directly interfere with viral envelope protein and not 
with the SA (sialic acid) receptor on the cell surface. 
To evaluate the antiinfluenza activity after virus in-
fection, we performed the post treatment assay10. In 
the post treatment assay, the aqueous extract did not 
show viral inhibition, whereas the ethanolic extract 
showed 100% reduction at the concentrations of 
60μg/ml. This data suggest that Ethanolic extract in-
hibit the Influenza virus infection by blockage of viral 
attachment by inhibition of viral HA protein, this is 
consistent with previous studies. 
CONCLUSION 
Conclusion of the study revealed the Aeglemarmelos 
fruit crude extract could be a potential resource for 
novel antiviral drugs. The plant extracts investigated 
could serve as capable candidates for the develop-
ment of third generation anti influenza drugs, thus 
challenging the neuraminidase drug resistant viruses 
in an attempt to safeguard human health and the 
global economy. Treatment with synergistically ac-
tive antiviral compound that have diverse mecha-
nism of action may provide several advantages such 
as greater potency, fewer side effects and toxicity and 
better clinical studies over single compound treat-
ment. The present findings persuade the need for 
clinical studies to investigate the therapeutic and 
prophylactic potential of extracts of Aeglemarmelos 
and to extend this study to other respiratory viruses. 
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